US · LVTX
LAVA Therapeutics N.V.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Utrecht 3584 CM
- Website
- lavatherapeutics.com
Price · as of 2024-12-31
—
Market cap 42.48M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $39.43 | — |
| Intrinsic Value(DCF) | $31.12 | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $4.68 | $39.79 | $4.28 | $0.00 | $0.00 |
| 2022 | $1.99 | $85.46 | $1.81 | $0.00 | $0.00 |
| 2023 | $2.32 | $566.62 | $0.26 | $0.00 | $84.86 |
| 2024 | $1.44 | $39.43 | $50.90 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates LAVA Therapeutics N.V.'s (LVTX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $39.43
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$31.12
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LVTX | LAVA Therapeutics N.V. | $1.62 | 42.48M | +2,341% | +1,827% | — | — | -1.54 | 1.39 | 3.22 | 1.39 | — | 1.39 | 100.00% | -247.81% | -209.60% | -63.64% | 72.75% | -27.52% | 0.19 | -57.66 | 4.40 | 4.25 | 1.27 | -4013.00% | 7701.00% | -5229.00% | -50.64% | -1.09 | 47.94% | 0.00% | 0.00% | 0.00% | 1.10 | 1.67 | -2.73 | -2.75 |
| CALC | CalciMedica, Inc. | $2.97 | 41.5M | — | — | — | — | -1.84 | 1.75 | — | -0.27 | — | 1.75 | 0.00% | — | — | -121.42% | 659.51% | -85.68% | 0.00 | — | 5.34 | 5.07 | 0.33 | -8405.00% | — | -1803.00% | -83.97% | -5.74 | 576.40% | 0.00% | 0.00% | 9.55% | -0.27 | -0.31 | — | -11.56 |
| CELU | Celularity Inc. | $1.84 | 42.25M | +2,561% | -73% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| ELUT | Elutia Inc. | $0.96 | 40.8M | +2,313% | +16% | — | — | -1.50 | -1.74 | 3.31 | -2.01 | — | -1.48 | 43.93% | -146.26% | -221.33% | 127.15% | 103.81% | -135.63% | -0.53 | -7.46 | 0.69 | 0.54 | -0.25 | -1014.00% | -150.00% | 545.00% | -28.90% | -0.60 | 67.88% | 0.00% | 0.00% | 1.47% | -2.59 | -3.95 | 3.78 | -11.28 |
| LTRN | Lantern Pharma Inc. | $3.55 | 38.34M | — | — | — | — | -1.90 | 1.86 | — | -0.70 | 0.00 | 1.86 | 0.00% | — | — | -66.93% | 1620.51% | -60.04% | 0.01 | — | 5.83 | 5.54 | 0.33 | 13125510.00% | — | 2409.00% | -45.25% | -4.11 | 1300.25% | 0.00% | 0.00% | 0.00% | -0.70 | -0.88 | — | -0.66 |
| PDSB | PDS Biotechnology Corpora… | $0.91 | 42.23M | — | — | — | — | -1.19 | 2.36 | — | -0.74 | — | 2.36 | 0.00% | — | — | -166.65% | 954.97% | -71.81% | 1.15 | -7.77 | 2.64 | 2.44 | 0.59 | -2590.00% | — | 423.00% | -78.19% | -2.05 | 943.09% | 0.00% | 0.00% | 0.00% | -0.69 | -0.71 | — | -6.50 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.58 | 39.53M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
| TPST | Tempest Therapeutics, Inc… | $9.95 | 44.18M | — | — | — | — | -7.25 | 15.85 | — | -7.18 | — | 15.85 | 0.00% | — | — | -182.35% | -676.64% | -89.90% | 0.80 | -31.93 | 2.21 | 2.13 | 0.37 | -2147.00% | — | 2156.00% | -11.03% | -2.32 | -538.75% | 0.00% | 0.00% | 0.00% | -6.86 | -8.62 | — | -1.70 |
| TVRD | Tvardi Therapeutics, Inc. | $4.22 | 39.57M | +2,690% | +40% | — | +60,628% | -0.32 | -4.89 | 3.15 | -0.46 | -0.01 | -4.89 | 88.62% | -781.57% | -992.95% | 212.65% | 134.22% | -200.11% | -9.68 | -6.58 | 11.03 | 10.67 | -0.10 | 241838.00% | -6596.00% | 19450.00% | -276.02% | -15.34 | 149.93% | 0.00% | 0.00% | 0.00% | -0.52 | -0.47 | 4.06 | -26.80 |
| XLO | Xilio Therapeutics, Inc. | $0.82 | 42.26M | — | — | — | — | -0.84 | 2.76 | 7.67 | -0.03 | — | 2.76 | 100.00% | -954.95% | -918.05% | -214.02% | 466.54% | -88.24% | 0.46 | -605.82 | 2.21 | 2.03 | 0.81 | -6079.00% | — | -7335.00% | -37.86% | -0.67 | 141.80% | 0.00% | 0.00% | 28.58% | -0.02 | -0.08 | 0.24 | -9.18 |
About LAVA Therapeutics N.V.
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-051, which is in Phase 1/2a clinical trial for blood cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia; and LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is also developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 and LAVA-1278, which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
- CEO
- Stephen Allen Hurly
- Employees
- 34
- Beta
- 0.50
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($31.12 ÷ —) − 1 = — (DCF, example).